TAKP34.SA Takeda Pharmaceutical Company Limited
- Market cap
- BRL 348B
- P/E
- 294.6x
- P/B
- 1.35x
- ROE
- 8.2%
- Dividend yield
- 2.50%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is TAKP34.SA undervalued?
Graham numberThe Graham number of Takeda Pharmaceutical Company Limited cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Takeda Pharmaceutical Company Limited fundamental analysis
No fundamental analysis for Takeda Pharmaceutical Company Limited yet.
Takeda Pharmaceutical Company Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gamm…
Full company profileTakeda Pharmaceutical Company Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Takeda Pharmaceutical Company Limited annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.73T | 1.77T | 2.10T | 3.29T | 3.20T | 3.57T | 4.03T | 4.26T | 4.58T | 4.51T | 4.81T |
| Gross Profit | 1.17T | 1.27T | 1.45T | 2.20T | 2.20T | 2.46T | 2.78T | 2.84T | 3.00T | 2.93T | 3.22T |
| Operating Income | 147B | 240B | 223B | 97.5B | 509B | 533B | 533B | 249B | 357B | 464B | 973B |
| EBITDA | - | 431B | 416B | 672B | 1.17T | 1.01T | 1.21T | 900B | 1.07T | 727B | 1.55T |
| Net Income | 115B | 187B | 135B | 44.2B | 376B | 230B | 317B | 144B | 108B | -152B | 611B |
| EPS | 147 | 239 | 87 | 28 | 240 | 148 | 204 | 92 | 69 | -96 | 383 |
| Balance Sheet | |||||||||||
| Total Assets | 4.35T | 4.11T | 13.8T | 12.8T | 12.9T | 13.2T | 14.0T | 15.1T | 14.2T | 15.5T | 15.3T |
| Total Liabilities | 2.45T | 2.11T | 8.61T | 8.10T | 7.74T | 7.49T | 7.60T | 7.83T | 7.31T | 8.08T | 7.85T |
| Shareholders' Equity | 1.89T | 2.00T | 5.18T | 4.72T | 5.17T | 5.68T | 6.35T | 7.27T | 6.94T | 7.43T | 7.42T |
| Cash & Short-term Investments | 376B | 375B | 726B | 653B | 1.00T | 875B | 554B | 473B | 406B | 595B | 419B |
| Total Debt | 1.00T | 986B | 5.27T | 4.51T | 4.61T | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 240B | 399B | 328B | 670B | 1.01T | 1.12T | 977B | 716B | 1.06T | 1.04T | 864B |
| Capital Expenditure | 112B | 128B | 134B | 218B | 236B | 123B | 634B | 481B | 348B | 415B | 318B |
| Free Cash Flow | - | 250B | 194B | 452B | 774B | 937B | 343B | 236B | 678B | 627B | 546B |
| Ratios | |||||||||||
| ROE | 6.1% | 9.4% | 2.6% | 0.9% | 7.3% | 4.0% | 5.0% | 2.0% | 1.6% | -2.1% | 8.2% |
| ROA | 2.6% | 4.6% | 1.0% | 0.3% | 2.9% | 1.7% | 2.3% | 1.0% | 0.8% | -1.0% | 4.0% |
| Net Profit Margin | 6.6% | 10.6% | 6.4% | 1.3% | 11.8% | 6.4% | 7.9% | 3.4% | 2.4% | -3.4% | 12.7% |
| Debt to Equity | 0.53x | 0.49x | 1.02x | 0.96x | 0.89x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Takeda Pharmaceutical Company Limited dividends
- Dividend yield
- 2.50%
- Forward dividend
- 2.69 BRL
- Payout ratio
- -
- Ex-dividend date
- Sep 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 312B | 197 | - |
| 2025 | JPY 302B | 192 | 280.3% |
| 2024 | JPY 287B | 183 | 199.3% |
| 2023 | JPY 279B | 180 | 88.1% |
| 2022 | JPY 284B | 183 | 123.3% |
| 2021 | JPY 283B | 181 | 75.4% |
| 2020 | JPY 283B | 181 | 638.7% |
| 2019 | JPY 143B | 92 | 105.7% |
| 2018 | JPY 142B | 182 | 75.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Takeda Pharmaceutical Company Limited
Ownership data of Takeda Pharmaceutical Company Limited is not available yet.
Takeda Pharmaceutical Company Limited company profile
- Company name
- Takeda Pharmaceutical Company Limited
- Ticker
- TAKP34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 47,029
- Fiscal year end
- March
- Address
- 1-1, Nihonbashi-Honcho 2-chome, Chuo, Japan, 103-8668
- Phone
- 81 3 3278 2111
- Website
- takeda.com
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
Takeda Pharmaceutical Company Limited management
10- Mr. Milano FurutaCFO & Director · born 1978
- Dr. Andrew S. Plump M.D., Ph.D.President of Research & Development and Representative Director · born 1965
- Ms. Julie KimCEO, President & Director · born 1970
- Dr. Seigo IzumoChair of Management Board
- Mr. Haruhiko HirateMember of Management Board · born 1957
- Mr. Salvatore Alesci M.D., Ph.D.Member of Management Board and Head of R&D Global Science & Biomedical Policy · born 1975
- Michael FoxChief Operating Officer
- Norimasa TakedaChief Accounting Officer & Corporate Controller
- Mr. Iwaaki TaniguchiSenior Vice President of Corporate Finance & Controlling Department
- Mr. Gabriele RicciChief Data & Technology Officer · born 1978